Citations

Clear

246 citation(s) found for "Study, Alfa".

P2‐011: Systematics of the Alzheimer's disease neuroimaging initiative phantom
Gunter, Jeff, Borowski, Bret, Ward, Chadwick P., Britson, Paula J., Felmlee, Joel P. , Schuff, Norbert, Weiner, Michael W. , Bernstein, Matt A. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_11 | Pages: No page available

10.1016/j.jalz.2008.05.1091 Get It

Magnetic Resonance Elastography Assessment of Focused Ultrasound Surgery in Cancer Models: A Pilot Study
Primak, S. V., Yuan, Le , Glaser, Kevin J. , Reynold, Carol A., Lai, Jinping , Rossman, Philip J., Felmlee, Joel P. , Roberts, Lewis R. , Ehman, Richard L.

Mayo Clinic

Advances in Bioengineering, Biomedical and Safety Systems | April 3, 2008 | Volume: No volume available | Issue: No issue available | Pages: 41-45

10.1115/imece2006-16010 Get It

MRI guided focused ultrasound (FUS) has been shown to create thermal lesions where tissue stiffness changes significantly. To assess the correlation between tissue stiffness change and tissue ablation, a pilot animal based study was conducted to treat LNCaP tumors in vivo and Hep3B tumors immediately post mortem. MR elastography was used to analyze tissue stiffness before and after ablation. Treated tissue was excised immediately after each experiment and processed by routine histological analysis. Four prostate cancer tumors and four liver cancer tumors showed, on average, a threefold increase in stiffness due to FUS thermal treatment. Histology showed complete (100%) coagulation necrosis in these cases. These data suggest that MRE may be an effective means to assess tissue ablation.
Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity
Buxbaum, Joel N. , Ye, Zhengyi, Reixach, Natàlia , Friske, Linsey, Levy, Coree L., Das, Pritam , Golde, Todd E. , Masliah, Eliezer , Roberts, Amanda R., Bartfai, Tamás

Mayo Clinic

Proceedings of the National Academy of Sciences | February 12, 2008 | Volume: 105 | Issue: 7 | Pages: 2681-2686

10.1073/pnas.0712197105 | PMID 18272491 Get It

Cells that have evolved to produce large quantities of secreted proteins to serve the integrated functions of complex multicellular organisms are equipped to compensate for protein misfolding. Hepatocytes and plasma cells have well developed chaperone and proteasome systems to ensure that secreted proteins transit the cell efficiently. The number of neurodegenerative disorders associated with protein misfolding suggests that neurons are particularly sensitive to the pathogenic effects of aggregates of misfolded molecules because those systems are less well developed in this lineage. Aggregates of the amyloidogenic (Aβ 1–42 ) peptide play a major role in the pathogenesis of Alzheimer's disease (AD), although the precise mechanism is unclear. In genetic studies examining protein–protein interactions that could constitute native mechanisms of neuroprotection in vivo , overexpression of a WT human transthyretin (TTR) transgene was ameliorative in the APP23 transgenic murine model of human AD. Targeted silencing of the endogenous TTR gene accelerated the development of the neuropathologic phenotype. Intraneuronal TTR was seen in the brains of normal humans and mice and in AD patients and APP23 mice. The APP23 brains showed colocalization of extracellular TTR with Aβ in plaques. Using surface plasmon resonance we obtained in vitro evidence of direct protein–protein interaction between TTR and Aβ aggregates. These findings suggest that TTR is protective because of its capacity to bind toxic or pretoxic Aβ aggregates in both the intracellular and extracellular environment in a chaperone-like manner. The interaction may represent a unique normal host defense mechanism, enhancement of which could be therapeutically useful.
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment
Fleisher, Adam , Sun, Shichang , Ward, Chad, Gamst, Anthony, Petersen, Ronald C. , Jack, Clifford R. , Aisen, Paul , Thal, L. J., Taylor, Catherine Louise , Jack, Clifford R

Mayo Clinic

Neurology | January 14, 2008 | Volume: 70 | Issue: 3 | Pages: 191-199

10.1212/01.wnl.0000287091.57376.65 | PMID 18195264 Get It

The Compartments of the Foot: A 3-Tesla Magnetic Resonance Imaging Study with Clinical Correlates for Needle Pressure Testing
Reach, John S., Amrami, Kimberly K. , Felmlee, Joel P. , Stanley, David , Alcorn, Joseph, Turner, Norman S.

Mayo Clinic

Foot & Ankle International | June 8, 2007 | Volume: 28 | Issue: 5 | Pages: 584-594

10.3113/fai.2007.0584 | PMID 17559766 Get It

Background: Reliable measurement of subfascial pressures represents an essential part of compartment syndrome management. To date, there is neither consensus on the number or location of foot compartments, nor a standardized protocol for needle placement. The purpose of this study was to devise a new system using 3-Tesla MRI that assesses the number and location of these compartments. Methods: To document the specific location of foot compartments, high resolution 3-Tesla MRI (General Electric, Milwaukee, WI) was coupled with a dedicated transmit-receive high signal-to-noise foot/ankle coil (IGC-Medical Advances, Milwaukee, WI). Individual compartments were highlighted and mapped to T1-weighted MRI. Three-dimensional image analysis allowed standardized needle placement recommendations. Results: Six feet from healthy volunteers were imaged. From these, ten compartments were described: (1) medial, (2) central superficial, (3) central deep (adductor), (4) lateral, (5–8) interossei, (9) calcaneal, and (10) skin. Optimal needle placement and depth were identified. Conclusions: The proposed system allowed us to assess the number and location of foot compartments. Computer image analysis enabled us to define exact points for needle insertion and depth of penetration for accurate pressure monitoring.
P‐038: MRI system tracking and correction using the adni phantom
Gunter, Jeff, Britson, Paula J., Felmlee, Joel P. , Schuff, Norbert, Weiner, Michael W. , Bernstein, Matt A. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_1 | Pages: No page available

10.1016/j.jalz.2007.04.254 Get It

O1–04–04: The Alzheimer's disease neuroimaging initiative: Progress report
Weiner, Michael W. , Thal, Leon J., Petersen, Ronald C. , Jagust, William J. , Trojanowski, John Q., Shaw, Leslie M. , Gamst, Anthony, Jack, Clifford R. , Trojanowski, John Q., Toga, Arthur W. , Beckett, Laurel

Mayo Clinic

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.080 Get It

O1–05–03: PET measurements of posterior cingulate glucose metabolism are superior to MRI measurements of hippocampal volume in distinguishing cognitively normal persons at differential genetic risk for Alzheimer's disease
Reiman, Eric M. , Alexander, Gene E. , Reschke, Cole, Lee, Wendy , Smilovici, Oded, Buckley, Shannon, Sacrey, Diana Truran, Schuff, Norbert, Müller, Stig , Weiner, Michael W. , Caselli, Richard J., Chen, Kewei , Smilovici, Oded

Mayo Clinic

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.070 Get It

A quality control program for MR‐guided focused ultrasound ablation therapy
Wu, Tao , Felmlee, Joel P.

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 22, 2007 | Volume: 3 | Issue: 2 | Pages: 162-167

10.1120/jacmp.v3i2.2584 | PMID 11958655 Get It

In this study, we propose a quality control program for MR‐guided focused ultrasound (FUS) ablation treatment to assess FUS beam positioning accuracy, FUS power delivery accuracy, MR imaging quality, and FUS ablation system safety. A total of 353 sonication points in Lucite cards were measured, the average placement errors were in the SI direction and in the LR direction. Temperature elevation was calculated from MR phase difference images and the measured water proton chemical shift (WPCS) temperature coefficient. WPCS temperature calibration for phantoms yielded a temperature coefficient of 0.011 ppm/°C. Sixteen experiments were conducted using six different phantoms to test the reliability of FUS power delivery. SNR and RF power calculated from phantom images were analyzed and stored at the MR console. A computer program was developed to integrate the system power delivery and the MR image quality control into one automated process. In the clinical trial at our institution, we expect this quality control program to be carried out before each patient treatment. If measured quality control values exceeds or below the preset values, a system service and retest should be conducted before the treatment.PACS number(s): 87.61.–c, 87.54.–n
National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards
Hachinski, Vladimir , Iadecola, Costantino , Petersen, Ron, Breteler, Monique M.B. , Nyenhuis, David L. , Black, Sandra E. , DeCarli, Charles , Merino, José G. , Kalaria, Raj N. , Vinters, Harry V. , Wallin, Anders, Dichgans, Martin , Marler, John R., Leblanc, Gabrielle G., DeCarli, Charles , Powers, William J. , Holtzman, David M. , Rosenberg, Gary A. , Dichgans, Martin

Mayo Clinic

Stroke | August 17, 2006 | Volume: 37 | Issue: 9 | Pages: 2220-2241

10.1161/01.str.0000237236.88823.47 | PMID 16917086 Get It

Background and Purpose— One in 3 individuals will experience a stroke, dementia or both. Moreover, twice as many individuals will have cognitive impairment short of dementia as either stroke or dementia. The commonly used stroke scales do not measure cognition, while dementia criteria focus on the late stages of cognitive impairment, and are heavily biased toward the diagnosis of Alzheimer disease. No commonly agreed standards exist for identifying and describing individuals with cognitive impairment, particularly in the early stages, and especially with cognitive impairment related to vascular factors, or vascular cognitive impairment. Methods— The National Institute for Neurological Disorders and Stroke (NINDS) and the Canadian Stroke Network (CSN) convened researchers in clinical diagnosis, epidemiology, neuropsychology, brain imaging, neuropathology, experimental models, biomarkers, genetics, and clinical trials to recommend minimum, common, clinical and research standards for the description and study of vascular cognitive impairment. Results— The results of these discussions are reported herein. Conclusions— The development of common standards represents a first step in a process of use, validation and refinement. Using the same standards will help identify individuals in the early stages of cognitive impairment, will make studies comparable, and by integrating knowledge, will accelerate the pace of progress.